Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Biotech Digital MeetBiotech Digital Meet
Not Confirmed
Not Confirmed
17-21 February, 2025
Not Confirmed
Not Confirmed
19-21 February, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Biotech Digital MeetBiotech Digital Meet
Webinar
Not Confirmed
17-21 February, 2025
Industry Trade Show
Not Confirmed
19-21 February, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/fda-s-first-generic-approvals-slump-21-in-2024-novartis-top-seller-entresto-cancer-blockbuster-tasigna-lead-2024-patent-cliff
Details:
The collaboration aims on the development of a novel RNAi-based therapy for the treatment of retinal diseases including geographic atrophy (GA), an advanced form of age-related macular degeneration.
Lead Product(s): Undisclosed
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Oligonucleotide
Sponsor: Bausch & Lomb Incorporated
Deal Size: $485.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 10, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Bausch & Lomb Incorporated
Deal Size : $485.0 million
Deal Type : Collaboration
City Therapeutics, Bausch + Lomb Partner on Preclinical RNAi Eye Drug
Details : The collaboration aims on the development of a novel RNAi-based therapy for the treatment of retinal diseases including geographic atrophy (GA), an advanced form of age-related macular degeneration.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
January 10, 2025
ABOUT THIS PAGE